Physician overview
30 Million

Viable Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs)

mCELL package and three vials
Purpose-built cell therapy

A Consistent, Ready-to-Use BM-MSC Product

  • Designed to alleviate pain, increase joint function and speed wound healing.
  • Sourced from screened, healthy donors ages 18-25; no painful aspiration process
  • Fully characterized for biological activity
  • Animal-origin-free and DMSO-free manufacturing platform, designed to preserve cell quality and efficacy
BM-MSCs, like mCELL™, respond to the local tissue environment through coordinated signaling pathways. Together, these signals limit ongoing tissue damage, support healing, and promote regeneration.
Vascularization
Matrix repair
Immunomodulation
Why bone marrow-derived MSCs

The Most Established Clinical Evidence

Bone-marrow MSCs, like mCELL™, have the most established clinical evidence and the only lineage with an FDA-approved therapeutic precedent.

Immunomodulation chart showing greater IDO activity for bone marrow-derived MSCs
Vascular signaling chart showing greater VEGF secretion for bone marrow-derived MSCs

Outperforms Umbilical MSCs

Greater IDO activity and VEGF secretion in standardized laboratory testing

FDA-Approved Precedent

Only MSC source represented in an FDA-approved therapy

Deepest Orthopedic Evidence Base

Phase 3 knee OA data (146 pts) and randomized DDD data (100 pts; 36 mo)

Rationale Grounded in Anatomy

Physiologic stem-cell source already leveraged by BMAC and microfracture

Sourcing & Delivery

From donor-bone marrow to your clinic

Four-step mCELL sourcing, manufacturing and delivery process
1

Bone Marrow Harvest

Screened, healthy donors age 18-25. 21 CFR 1271 compliant accredited institution.

2

Master Cell Bank

Qualified and selected for potency.

3

mCELL™ GMP Manufacturing

Fill, finish and release. DMSO-free cryopreservation.

4

mCELL™ Delivery

Shipping in a qualified -80°C container. Thaw and inject. Lot-specific COA.

AABB, AATB and FACT accreditation marks

Quality Standards & Third-Party Qualification

FDA-registered facility

Manufactured in an FDA-registered, cGMP-compliant facility with 34+ years of operation

cGMP manufacturing

ISO 5 / ISO 7 cleanrooms, environmentally controlled and monitored 24/7

ISO 5 and ISO 7 cleanrooms

Validated aseptic process, qualified equipment, trained and accountable personnel

End-to-end lot traceability from donor to physician

More than 30 years of bioprocessing experience

Quality Assurance oversight and release

Donor eligibility and infectious-disease screening per 21 CFR Part 1271

Testing is performed by independent laboratories at both ends of the process.

Master Cell Bank

Independently qualified for sterility, mycoplasma, adventitious agents, identity, and karyotype/genetic stability.

Final Product

Every lot tested against predefined release specifications and documented on the Certificate of Analysis.

Safety & Identity

Sterility, endotoxin, mycoplasma, adventitious agents, and MSC surface markers.

Viability & Function

Post-thaw viability, immunomodulatory activity, and IDO.